In addition to the previously described BRAF and MEK inhibitor responses, multiple tumours exhibited notable sensitivities to dinaciclib (CDK inhibitor), doxorubicin (DNA synthesis inhibitor), vorinostat (histone deacetylase inhibitor) and ganetespib (heat shock protein 90 inhibitor) (Fig. 2a). The gene discussed is BRAF; the disease is neoplasm.